Jun. 13 at 1:03 PM
$XLO
🔁 This allows them to time full ownership strategically.
Almost no additional cost
They’ve already paid
$0.7499 per warrant; exercising requires just
$0.0001 more.
So it’s like they’ve already bought the share — they’re just waiting to “activate” it.
Bundled with traditional Series A, B, and C warrants
Each pre-funded warrant comes with traditional warrants exercisable at
$0.75. These only gain value if the share price rises, making them a bet on future upside.
🧠 Conclusion:
Investors aren’t delaying conversion because they’re bearish, but because they’re managing ownership limits and waiting for the right moment.
Plus, the involvement of big names like Gilead, AbbVie, and Takeda shows strong long-term confidence in Xilio (XLO), especially with clinical milestones ahead.
